PharmaCyte Biotech Inc Asset Resilience Ratio
PharmaCyte Biotech Inc asset resilience ratio. PharmaCyte Biotech Inc (PMCB) has an Asset Resilience Ratio of 39.52% as of April 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PharmaCyte Biotech Inc defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of PharmaCyte Biotech Inc (2009–2026)
Asset resilience ratio of PharmaCyte Biotech Inc from 2009 to 2026. This chart shows how PharmaCyte Biotech Inc's Asset Resilience Ratio has changed over time. Read total liabilities of PharmaCyte Biotech Inc for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down PharmaCyte Biotech Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see PMCB asset base.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $18.48 Million | 39.52% |
| Total Liquid Assets | $18.48 Million | 39.52% |
Asset Resilience Insights
- Very High Liquidity: PharmaCyte Biotech Inc maintains exceptional liquid asset reserves at 39.52% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
PharmaCyte Biotech Inc Industry Peers by Asset Resilience Ratio
Compare PharmaCyte Biotech Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL |
Biotechnology | 1.36% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA |
Biotechnology | 53.11% |
|
Gempharmatech Co. Ltd. A
SHG:688046 |
Biotechnology | 23.95% |
|
Vor Biopharma Inc
NASDAQ:VOR |
Biotechnology | 74.48% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
|
Guangdong VTR Bio-Tech Co Ltd
SHE:300381 |
Biotechnology | 4.98% |
PharmaCyte Biotech Inc Asset Resilience Ratio by Year (2009–2026)
PharmaCyte Biotech Inc asset resilience ratio by year from 2009 to 2026. The table below shows the annual Asset Resilience Ratio data for PharmaCyte Biotech Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2026-04-30 | 39.52% | $18.48 Million | $46.75 Million | +38.86pp |
| 2025-04-30 | 0.66% | $366.32K | $55.17 Million | -- |
| 2024-04-30 | 0.00% | $0.00 | $59.90 Million | -- |
| 2020-04-30 | 25.50% | $1.57 Million | $6.17 Million | +24.98pp |
| 2009-04-30 | 0.52% | $31.18K | $6.04 Million | -- |
About PharmaCyte Biotech Inc
PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer. It also devel… Read more